Established in 2013, Johnson & Johnson’s Office of the Chief Medical Officer (OCMO) is a global team encompassing safety colleagues from across all sectors of Johnson & Johnson. Functionally independent from commercial interests, we focus entirely on the safety of all products across the Johnson & Johnson Family of Companies. Our approach is reinforced by a cutting-edge single medical safety standard to which all of our products are held.
The OCMO takes an evidence- and science-based, ethics- and values-driven approach to medical safety—with an emphasis on transparency. This has led to the development of policies and initiatives that keep the needs of patients and consumers at the center of our efforts.
The company's mission is to care for the world—one person at a time. Just ask Chief Medical Officer Joanne Waldstreicher, M.D., who's been leading the charge to improve the process by which very sick patients may apply for access to investigational medications.
A Q&A with Gary Eichenbaum, Ph.D., Vice President, Preclinical Science and Safety, Office of the Chief Medical Officer, Johnson & Johnson.
A Q&A with Jesse Berlin, Sc.D., Vice President and Global Head of Epidemiology, Johnson & Johnson, about why open access in scientific publishing is important and how Johnson & Johnson is helping pave the way forward.